Please use this identifier to cite or link to this item: http://hdl.handle.net/1959.13/931987

OpenURL Link
Title
Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC Study
Author/Creator
Dowsett, Mitch;  Cuzick, Jack;  Howell, Anthony;  Bugarini, Roberto;  Baehner, Frederick L.;  Shak, Steven;  Wale, Christopher;  Forbes, John;  Mallon, Elizabeth A.;  Salter, Janine;  Quinn, Emma;  Dunbier, Anita;  Baum, Michael;  Buzdar, Aman
Institution
The University of Newcastle. Faculty of Health, School of Medicine and Public Health
Description
Purpose: To determine whether the Recurrence Score (RS) provided independent information on risk of distant recurrence (DR) in the tamoxifen and anastrozole arms of the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trial. Patients and Methods: RNA was extracted from 1,372 tumor blocks from postmenopausal patients with hormone receptor positive primary breast cancer in the monotherapy arms of ATAC. Twenty-one genes were assessed by quantitative reverse transcriptase polymerase chain reaction, and the RS was calculated. Cox proportional hazards models assessed the value of adding AS to a model with clinical variables (age, tumor size, grade, and treatment) in node-negative (NO) and node-positive (N+) women. Results: Reportable scores were available from 1,231 evaluable patients (NO, n = 872; N+, n = 306; and node status unknown, n = 53); 72, 74, and six DRs occurred in NO, N+, and node status unknown patients, respectively. For both NO and N+ patients, AS was significantly associated with time to DR in multivariate analyses (P < .001 for NO and P = .002 for N+). AS also showed significant prognostic value beyond that provided by Adjuvant! Online (P < .001). Nine-year DR rates in low (RS < 18), intermediate (RS = 18 to 30), and high RS (RS≥31) groups were 4%, 12%, and 25%, respectively, in NO patients and 17%, 28%, and 49%, respectively, in N+ patients. The prognostic value of AS was similar in anastrozole- and tamoxifen-treated patients. Conclusion: This study confirmed the performance of AS in postmenopausal HR+ patients treated with tamoxifen in a large contemporary population and demonstrated that AS is an independent predictor of DR in NO and N+ hormone receptor positive patients treated with anastrozole, adding value to estimates with standard clinicopathologic features.
Relation
Journal of Clinical Oncology Vol. 28, Issue 11, p. 1829-1834
Publisher Link
http://dx.doi.org/10.1200/JCO.2009.24.4798
Date
2010
Publisher
American Society of Clinical Oncology
Keyword(s)
breast cancer;  chemotherapy;  tamoxifen;  anastrozole
Resource Type
journal article
Identifier
http://hdl.handle.net/1959.13/931987
Identifier
ISSN:0732-183X
Reviewed
Reviewed
2 Visitors 3 Hits 0 Downloads
Save/E-mail Citation
Citation Format
E-mail Address
Subject
"Journal of Clinical Oncology"
 
OR